Celltrion Healthcare, Foreign Investors Net Buy 321,142 Shares in Last 5 Days... Stock Price 155,500 KRW (+8.21%)
As of 9:30 AM on the 1st, Celltrion Healthcare is trading at 155,500 KRW, up 8.21% from the previous day. The trading volume is 1,129,809 shares, which is 69.44% of the previous day's volume. Celltrion Healthcare is known as the exclusive distributor of Celltrion's biosimilars.
On January 29, Hana Financial Investment researcher Sun Min-jung stated, "A decline in Truxima sales to the US is expected in 2021. However, sales estimates for new products could achieve surprisingly better-than-expected results, so Celltrion Healthcare's estimates may be sufficiently revised upward after quarterly earnings announcements. Additionally, as a plus factor, if the COVID-19 treatment Regkirona receives EUA approval from the US FDA, high growth similar to that of 2020 is expected to continue in 2021." She set the target price for Celltrion Healthcare at 175,000 KRW.
Over the past five days, individual investors have net sold 270,266 shares of Celltrion Healthcare, while foreigners and institutions have net bought 321,142 shares and net sold 42,044 shares, respectively.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- Individual Investors Absorb Foreign Sell-Off... Concerns Over Becoming "Cannon Fodder" Emerge
- Experts Shocked by Record Numbers: "Just the Tip of the Iceberg" — The Identity Behind the 90% Dominating Teens [Chuiyakgukga]⑨
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Cheaper Than Mychew, but Nowhere to Be Found... Fears of a 'Pediatric Medical Crisis' as Drug Makers Halt Production [Why&Next]](https://cwcontent.asiae.co.kr/asiaresize/307/2026051910065268365_1779152813.jpg)
